Codexis, Inc. (CDXS)
NASDAQ: CDXS · Real-Time Price · USD
1.750
+0.080 (4.79%)
At close: Mar 25, 2026, 4:00 PM EDT
1.780
+0.030 (1.70%)
After-hours: Mar 25, 2026, 7:59 PM EDT
Codexis Revenue
In the year 2025, Codexis had annual revenue of $70.39M with 18.61% growth. Codexis had revenue of $38.92M in the quarter ending December 31, 2025, with 81.34% growth.
Revenue (ttm)
$70.39M
Revenue Growth
+18.61%
P/S Ratio
2.26
Revenue / Employee
$482,103
Employees
146
Market Cap
159.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.39M | 11.04M | 18.61% |
| Dec 31, 2024 | 59.35M | -10.80M | -15.39% |
| Dec 31, 2023 | 70.14M | -68.45M | -49.39% |
| Dec 31, 2022 | 138.59M | 33.84M | 32.30% |
| Dec 31, 2021 | 104.75M | 35.70M | 51.69% |
| Dec 31, 2020 | 69.06M | 598.00K | 0.87% |
| Dec 31, 2019 | 68.46M | 7.86M | 12.98% |
| Dec 31, 2018 | 60.59M | 10.57M | 21.13% |
| Dec 31, 2017 | 50.02M | 1.19M | 2.43% |
| Dec 31, 2016 | 48.84M | 7.03M | 16.82% |
| Dec 31, 2015 | 41.80M | 6.50M | 18.40% |
| Dec 31, 2014 | 35.31M | 3.39M | 10.60% |
| Dec 31, 2013 | 31.92M | -56.38M | -63.85% |
| Dec 31, 2012 | 88.30M | -35.57M | -28.71% |
| Dec 31, 2011 | 123.87M | 16.76M | 15.65% |
| Dec 31, 2010 | 107.10M | 24.20M | 29.18% |
| Dec 31, 2009 | 82.91M | 32.43M | 64.25% |
| Dec 31, 2008 | 50.48M | 25.15M | 99.26% |
| Dec 31, 2007 | 25.33M | 13.21M | 108.90% |
| Dec 31, 2006 | 12.13M | 343.00K | 2.91% |
| Dec 31, 2005 | 11.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Precision BioSciences | 34.26M |
| Evaxion | 7.53M |
| Korro Bio | 6.39M |
| Cartesian Therapeutics | 2.80M |
| Humacyte | 1.57M |
| Milestone Pharmaceuticals | 1.55M |
| Molecular Partners AG | 856.30K |
| NeOnc Technologies Holdings | 59.99K |
CDXS News
- 13 days ago - Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform - Seeking Alpha
- 14 days ago - Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results - GlobeNewsWire
- 21 days ago - Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform - PRNewsWire
- 4 weeks ago - Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11 - GlobeNewsWire
- 6 weeks ago - Codexis Achieves ISO 9001:2015 Certification - GlobeNewsWire
- 2 months ago - Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics - PRNewsWire
- 4 months ago - Codexis Announces Signing of Lease for GMP Manufacturing Facility - GlobeNewsWire